RECURSION PHARMACEUTICALS, INC. current report, 20 April 2021

Full document

Business Context and Reporting Period

This Form 8-K filing by Recursion Pharmaceuticals, Inc. (RXRX) covers the date of April 20, 2021. The report documents the completion of the Company's initial public offering (IPO) and the subsequent corporate governance updates required to transition to a public entity.

Key Financial Metrics

The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. As an IPO closing report, the document focuses on capital structure changes rather than operational financial performance metrics.

Material Changes

  • IPO Completion: The Company closed its IPO on April 20, 2021, selling 27,878,787 shares of Class A common stock. This total includes 3,636,363 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares.
  • Corporate Governance: The Company filed an amended and restated certificate of incorporation and adopted amended and restated bylaws effective April 20, 2021, in connection with the IPO.
  • Trading Status: Class A common stock is registered on the Nasdaq Global Select Market under the symbol "RXRX".

Guidance, Outlook, and Risks

The filing does not contain forward-looking financial guidance or management commentary on future performance. It references the Company's Prospectus filed on April 16, 2021, for details regarding "Risk Factors" and the "Description of Capital Stock." The Company notes that material information may be disclosed via SEC filings, its website, press releases, and social media channels.

Investor Verification Checklist

  • Verify the final IPO share count and underwriter option exercise details in the attached Press Release (Exhibit 99.1).
  • Review the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) for changes to voting rights and corporate structure.
  • Consult the Prospectus filed on April 16, 2021, for comprehensive risk factors and use of proceeds not detailed in this 8-K.
  • Confirm the trading status of Class A common stock on the Nasdaq Global Select Market.